311 related articles for article (PubMed ID: 8445292)
1. In vitro evaluation of factor VIII--bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets.
Sultan Y; Loyer F
J Lab Clin Med; 1993 Mar; 121(3):444-52. PubMed ID: 8445292
[TBL] [Abstract][Full Text] [Related]
2. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation assay as a possible tool for assessment of reduced activity of clotting factors induced by antiphospholipid antibodies and in-vitro evaluation of treatment options.
Livnat T; Zivelin A; Tamarin I; Guetta V; Salomon O
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):661-6. PubMed ID: 19730246
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
5. The factor VIII bypassing activity of prothrombin complex concentrates: the roles of factor VIIa and of endothelial cell tissue factor.
Teitel JM
Thromb Haemost; 1991 Nov; 66(5):559-64. PubMed ID: 1803620
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII cofactor.
Warren DL; Morrissey JH; Neuenschwander PF
Biochemistry; 1999 May; 38(20):6529-36. PubMed ID: 10350471
[TBL] [Abstract][Full Text] [Related]
7. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations.
Bolliger D; Szlam F; Azran M; Koyama K; Levy JH; Molinaro RJ; Tanaka KA
Anesth Analg; 2010 Sep; 111(3):601-8. PubMed ID: 20686004
[TBL] [Abstract][Full Text] [Related]
8. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.
Rosenfeld SB; Watkinson KK; Thompson BH; Macfarlane DE; Lentz SR
Thromb Haemost; 2002 May; 87(5):925-6. PubMed ID: 12038803
[No Abstract] [Full Text] [Related]
10. Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available.
Wielders SJ; Béguin S; Hemker HC; Lindhout T
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1138-42. PubMed ID: 15072993
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.
Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP
Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
13. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation.
Kjalke M; Monroe DM; Hoffman M; Oliver JA; Ezban M; Roberts HR
Thromb Haemost; 1998 Oct; 80(4):578-84. PubMed ID: 9798973
[TBL] [Abstract][Full Text] [Related]
14. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
Livnat T; Martinowitz U; Zivelin A; Rima D; Kenet G
Thromb Haemost; 2011 Apr; 105(4):688-95. PubMed ID: 21225093
[TBL] [Abstract][Full Text] [Related]
15. The endothelial cell and the factor VIII bypassing activity of prothrombin complex concentrate.
Teitel JM; Ni HY; Freedman JJ; Garvey MB
Thromb Haemost; 1988 Oct; 60(2):226-9. PubMed ID: 3146140
[TBL] [Abstract][Full Text] [Related]
16. A possible mechanism of action of activated factor VII independent of tissue factor.
Monroe DM; Hoffman M; Oliver JA; Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S15-20. PubMed ID: 9819024
[TBL] [Abstract][Full Text] [Related]
17. Modeling the action of factor VIIa in dilutional coagulopathy.
Monroe DM
Thromb Res; 2008; 122 Suppl 1():S7-S10. PubMed ID: 18691504
[TBL] [Abstract][Full Text] [Related]
18. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
[TBL] [Abstract][Full Text] [Related]
19. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
Buchanan GR; Kevy SV
Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
[TBL] [Abstract][Full Text] [Related]
20. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
Klintman J; Astermark J; Berntorp E
Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
